SEC Form 4
Myriad Genetics Inc (MYGN) insider trading
In the 12 months to Nov 9, 2026, one MYGN insider reported open-market sales of $66.8K across 1 filing; 3 insiders bought $722.2K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $66.8K
- 1 filing · 1 insider
- Open-market purchases
- $722.2K
- 3 filings
- Pre-arranged sales (10b5-1)
- 1 of 1
- All $66.8K sold was pre-arranged
Who traded MYGN, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
MYGN daily close from Nov 10, 2025 to Nov 7, 2026, between $2.86 and $7.91, last $5.89. 1 sale and 3 purchase filings by 4 insiders, marked at their filing dates. S. Louise Phanstiel, Director: bought $494.7K across 1 filing, first filed Feb 27, 2026, last Feb 27, 2026. Samraat S. Raha, President and CEO: bought $199.8K across 1 filing, first filed Mar 9, 2026, last Mar 9, 2026. Rashmi Kumar, Director: sold $66.8K across 1 filing, first filed Jun 9, 2026, last Jun 9, 2026. Paul Bisaro, Director: bought $27.6K across 1 filing, first filed May 14, 2026, last May 14, 2026.
Largest mark · tap a row for others
S. Louise Phanstiel · Director
Purchase $494,722
104,507 shares at $4.73 avg
Filed Feb 27, 2026 · traded Feb 25
Close on filing date $4.61
S. Louise Phanstiel · Director
Director
$494.7K boughtSamraat S. Raha · President and CEO
President and CEO
$199.8K boughtRashmi Kumar · Director
Director
$66.8K soldPaul Bisaro · Director
Director
$27.6K boughtOpen-market trades
4 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| S. Louise Phanstiel | Director | — | $494.7K | 1 | — | |
| Samraat S. Raha | President and CEO | — | $199.8K | 1 | — | |
| Rashmi Kumar | Director | $66.8K | — | 1 | 100% of sales | |
| Paul Bisaro | Director | — | $27.6K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Rashmi Kumar Director | SalePre-arranged (10b5-1) | 15,000 | $4.46 | $66.8K | 171,889 | |
traded | Paul Bisaro Director | Purchase | 7,500 | $3.69 | $27.6K | 97,441 | |
traded | Samraat S. Raha President and CEO | Purchase | 40,000 | $5.00 | $199.8K | 493,104 | |
traded | S. Louise Phanstiel Director | Purchase | 104,507 | $4.73 | $494.7K | 281,951 |
GET /stocks/filings/vX/form-4?tickers=MYGN&filing_date.gte=2025-11-09&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"MYGN"
],
"issuer_cik": "0000899923",
"owner_cik": "0001824720",
"accession_number": "0001824720-26-000004",
"form_type": "4",
"filing_date": "2026-06-09",
"period_of_report": "2026-06-08",
"issuer_name": "MYRIAD GENETICS INC",
"issuer_trading_symbol": "MYGN",
"owner_name": "Kumar Rashmi",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-08",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 15000,
"transaction_price_per_share": 4.4562,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 171889,
"transaction_value": 66843,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.37 to $4.63, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"MYGN"
],
"issuer_cik": "0000899923",
"owner_cik": "0001237253",
"accession_number": "0001237253-26-000002",
"form_type": "4",
"filing_date": "2026-05-14",
"period_of_report": "2026-05-14",
"issuer_name": "MYRIAD GENETICS INC",
"issuer_trading_symbol": "MYGN",
"owner_name": "Bisaro Paul",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-05-14",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 7500,
"transaction_price_per_share": 3.685,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 97441,
"transaction_value": 27637.5,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 58 records
- Tax withholding34 records
- Grants and awards24 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Myriad Genetics Inc's CEO sold stock?
No. Samraat S. Raha (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is MYGN’s insider data?
These are MYGN Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track MYGN insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for MYGN every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.